Bioelectric Skincare: Science vs Marketing

"Bioelectric" is one of the loudest skincare words of 2026. Brands promise "device-like" lifting from a cream, and suppliers are launching actives that claim to mimic electrostimulation at the cellular level. Some of it rests on real biology. Some of it is a leap from that biology to a product benefit that no independent study has yet shown.

This guide separates the two, using what is published, and gives formulators and founders a practical way to judge and word these claims before they go on a label.

1. What is skin bioelectricity?

Intact skin carries a small natural voltage, called the transepithelial potential. It builds up because ion channels and pumps, including the sodium-potassium pump, sit in different positions on the two sides of the epithelial cells. The surface ends up slightly negative compared with the tissue below, typically in the range of 10 to 60 millivolts.

The potential matters most after an injury. When the skin is wounded, the potential collapses at the wound, and a lateral electric field appears between the wound and the surrounding intact skin. Keratinocytes and several repair cells, including immune cells, fibroblasts and endothelial cells, migrate along that field toward the wound. This directed movement, called galvanotaxis, is an established step in wound re-epithelialisation.

So the starting point of the trend is genuine: skin cells do respond to electric fields. The open question is what that tells us about a cream.

2. Does electrical stimulation actually improve skin?

There are two very different bodies of evidence, and brands often blur them.

Wound healing

Published reviews support electrical stimulation as an approach to wound healing, and the research continues to grow. This evidence is about applied electrical stimulation on damaged skin, not about cosmetic products and not about healthy skin.

Facial microcurrent devices

For cosmetic use, microcurrent facial devices have some supportive studies, but they are small, and at least one commonly cited trial had no sham-treatment control, so improvements could have other causes. The evidence is encouraging, not conclusive.

"Device-like results" therefore sets a benchmark that is itself modest and still debated. A cream cannot borrow credibility from a device that has not fully earned it.

3. What do bioelectric ingredients claim?

A new category of actives is positioned as bioelectric. A 2026 example is Ignilyte from Vytrus Biotech, presented at in-cosmetics Global 2026 and shortlisted for an innovation award. It is made from dragon fruit (Hylocereus undatus) stem cells grown under controlled dark conditions to produce a secretome that the supplier describes as rich in glycoproteins and electrolytes. The supplier reports a two-step mechanism, first through P2X receptors and then an electroporation-like effect, and says it delivers visible results in 14 days.

Here is how those claims stack up. We attribute them to the supplier because that is where they come from.

None of this means the active does not work. It means the evidence currently sits with the supplier, and a brand building a product on it should ask for the full study before repeating the claim.

4. Why is a mechanism not the same as a benefit?

A mechanism diagram looks convincing, but biology is rarely one-directional. P2X receptors are ion channels that respond to extracellular ATP, and they are present on keratinocytes. In the skin-barrier research, the picture is mixed: in barrier-disruption studies, P2X receptor agonists delayed barrier recovery while P2X antagonists accelerated it, and strong ATP signalling through the P2X7 receptor is linked to inflammation in skin conditions.

This is not evidence against any specific ingredient. It shows that "activates a receptor" is not the same as "improves skin", and that the effect depends on the context, the dose and the tissue state. Only a controlled study on the finished product can show the actual outcome.

5. How to judge the evidence behind an active

Use this checklist before you build a concept around any new active, bioelectric or not:

1. Who ran the study? Supplier-run, independent lab, or published and peer-reviewed?
2. Was there a control? A vehicle or placebo group, ideally randomised and blinded.
3. How many people, and for how long? A small group over a few weeks supports a modest claim.
4. What was measured? Instrumental readings (elasticity, wrinkle depth) are stronger than self-assessment alone.
5. Was it your formula? Results at the supplier's test dose in their test base do not automatically carry over to your finished product.
6. Is the claim comparative? "As effective as a device" needs a head-to-head study.

6. How should you word bioelectric claims?

In the EU, Regulation (EU) No 655/2013 sets six common criteria for cosmetic claims: legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making. The evidential-support criterion requires adequate and verifiable evidence, and any study used must be relevant to the product and to the benefit claimed. Other markets have their own rules, so confirm the requirements for each country where you sell.

In practice, that leads to a few simple rules:

• Tie the claim to the measurement. If a study on your finished formula showed a change in a skin-firmness reading, claim the visible, measured benefit, nothing broader.
• Avoid device comparisons ("as effective as", "alternative to") unless you hold a head-to-head study.
• Avoid medical-sounding terms such as mesotherapy, which imply a procedure and a medical effect.
• Keep science language accurate. "Inspired by the skin's natural bioelectric signalling" is a statement of concept; "reactivates your skin's bioelectricity" is a performance claim that needs evidence.

7. Practical formulation notes

If you do decide to work with a bioelectric-positioned active such as Ignilyte, the supplier's technical guide gives these handling points. They are supplier data, so confirm them against the current documentation and your own stability tests:

• Use level: 1.5 to 3% in the finished formula.
• Process: add at the end, preferably below 40 °C, during the cooling phase.
• Formats: works in O/W and W/O emulsions, aqueous gels and serums; dispersible in water and in ethanol solutions up to 20% ethanol.
• pH: stated range of 3.0 to 8.0 in the final formula.
• Appearance: may add a light yellowish tint at the upper use level, more noticeable in clear gels than in emulsions.

8. Frequently asked questions

Sources and further reading

• PMC — Advances in electrical stimulation for wound healing
• Review — Electric field: a key signal in wound healing
• Journal of Investigative Dermatology — Purinergic signaling in healthy and diseased skin
• Journal of Investigative Dermatology — P2X purinergic receptor antagonist accelerates skin barrier repair
• EUR-Lex — Commission Regulation (EU) No 655/2013, common criteria for cosmetic claims
• Vytrus Biotech — in-cosmetics Global 2026 announcement (supplier source)